We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

5,400+

Open access books available

134,000+

165M+

International authors and editors

156 Countries delivered to Our authors are among the

Top 1% most cited scientists

12.2%

Downloads

Contributors from top 500 universities

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

### Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com

## Meet the editor

Dr. Elisabeth Eppard is a radiochemist working on the development and process implementation of new compounds for theranostic application. In 2013 she obtained her Ph.D. under Prof. Rösch at the Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Germany, where she worked on radiometal-based radiopharmaceuticals. After four years as a junior research group leader in the Department of Nuclear Med-

icine, University Hospital Bonn, Germany, Dr. Eppard joined Positronpharma SA, Santiago, Chile, as a senior scientist in 2018. There she was responsible for research and clinical applications based on 68Ga-, 44Sc-, and 177Lu-labelled theranostics. Since 2021, she has been a radiochemist in the Department of Nuclear Medicine, University Hospital Magdeburg, Germany, where she is continuing her research.

Contents

**Section 1**

**Section 2**

*by Arghya Sett*

**Section 3**

Conditions

and Bioremediation

*and V.B. Sameer Kumar*

*and Renata Mikołajczak*

Pretargeted Theranostics

**Preface XI**

Theranostic Radiopharmaceuticals **1**

**Chapter 1 3**

**Chapter 2 23**

Theranostics Based on Naturally Occuring Components **43**

**Chapter 3 45**

**Chapter 4 61**

Theranostics with Nanomaterials **83**

**Chapter 5 85**

**Chapter 6 119**

*by Justyna Pijarowska-Kruszyna, Piotr Garnuszek, Clemens Decristoforo* 

*by Markus Staudt, Matthias M. Herth and Christian B.M. Poulie*

Extracellular Vesicles: "Stealth Transport Aircrafts" for Drugs

Graphene-Based Nanosystems: Versatile Nanotools for Theranostics

*by Marlene Lúcio, Eduarda Fernandes, Hugo Gonçalves, Sofia Machado,* 

Regulation of Angiogenesis Using Nanomaterial Based Formulations: An Emerging Therapeutic Strategy to Manage Multiple Pathological

*by Aswini Poyyakkara, Sruthi Thekkeveedu, Sharath S. Shankar* 

*Andreia C. Gomes and Maria Elisabete C.D. Real Oliveira*

Aptamers: Magic Bullet for Theranostic Applications

*by Chunying Liu, Xuejing Lin and Changqing Su*

Radiopharmaceutical Precursors for Theranostics

### Contents


Preface

In recent years the paradigm of "one-size-fits-all" in medicine has shifted successively to more patient-oriented treatment strategies [1, 2]. The aim of this personalized approach is to treat the right patient at the right time with the right drug to achieve maximum effect with minimal adverse effects. According to the definition of the U.S. National Cancer Institute, personalized medicine is "a form of medicine that uses information about a person's own genes or proteins to prevent, diagnose, or treat

To meet this challenge, individual patient treatment and accurate diagnosis is indispensable. This includes, but is not limited to, characterization, staging, and quantification of the underlying disease, all of which guide physician decisions for optimal treatment planning. Beyond that, deeper knowledge and understanding of the individual properties and differences of the same disease in different patients paves the way for the development of tailored drugs and for the treatment of the

In this context, so-called theranostics has importance. Though the term was established in 2002 as a portmanteau of "therapy" and "diagnostics," the concept itself has been adopted elsewhere and explored for decades [3]. Originally describing "any material that combines the modalities of therapy and diagnostic imaging,"

Since the pioneering work of Saul Hertz (1905–1950), the father of theranostics, who first applied radioactive iodine for therapy in 1941 and influenced strongly the management paradigm for diseases of the thyroid [5], the field has evolved and expanded greatly. Growing knowledge about the genesis of a disease and more sophisticated diagnostic and therapeutic techniques promote the research and

This book presents a selection of new developments in the area of theranostics and provides a comprehensive overview of the state of the art in this exciting discipline.

**Elisabeth Eppard**

Magdeburg, Germany

Klinik für Radiologie und Nuklearmedizin/ Universitätsklinikum Magdeburg A.ö.R.,

theranostics now commonly refers to image-guided therapy [4].

development of new theranostic materials and, ultimately, drugs.

disease."

individual patient's needs.
